Welcome to our dedicated page for BICYCLE THERAPEUTICS PLC SEC filings (Ticker: BCYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BICYCLE THERAPEUTICS PLC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BICYCLE THERAPEUTICS PLC's regulatory disclosures and financial reporting.
BCYC insider reported planned and recent share sales. The filing lists 2,937 restricted shares to be sold on 04/02/2026 as equity compensation. It also reports prior sales by Alethia Young of 3,289 shares on 04/02/2026 for $22,358.62 and 4,334 shares on 01/05/2026 for $28,113.16.
BCYC submitted a Form 144 reporting proposed sales of restricted common stock. The filing lists a proposed sale of 3,187 restricted shares dated 04/02/2026 and a proposed sale of 111 restricted shares dated 04/03/2026. The broker listed is Stifel Nicolaus & Company Inc. and the securities are Common Stock traded on Nasdaq.
Notice of proposed resale by an affiliate. The filing reports proposed sales of Common Stock associated with equity compensation: 1,317 shares reported on 04/02/2026 (value shown $8,952.97) and 1,115 shares reported on 01/05/2026 (value shown $7,194.47). The excerpt also lists restricted stock amounts of 2,093 and 312 shares on 04/02/2026 and 04/03/2026, respectively.
BCYC insider reported stock dispositions and planned restricted-stock sales. The filing lists 3,187 shares of restricted common stock intended to be sold on 04/02/2026 and 512 shares on 04/03/2026. It also reports prior sales of 2,827 shares on 04/02/2026 for $22,052.71 and 2,367 shares on 01/05/2026 for $15,271.61. The filing shows 50,269,082 shares outstanding as of 04/02/2026.
BCYC submitted a Form 144 notice regarding proposed sales of Common Stock by an issuer and recent restricted-stock dispositions. The filing lists proposed transfers of 4,624 shares (04/02/2026) and 1,093 shares (04/03/2026), and discloses prior sales of 3,244 shares (04/02/2026) and 3,416 shares (01/05/2026) with associated amounts shown.
The broker shown is Stifel Nicolaus & Company Inc and the market is Nasdaq. Transactions are labeled as Restricted Stock and Equity Compensation.
BCYC submitted a Form 144 notice disclosing proposed and recent restricted/common stock transactions. The filing lists proposed restricted stock sales of 3,937 shares dated 04/02/2026 and 1,093 shares dated 04/03/2026.
The filing also reports reported sales by Michael Skynner: 3,045 shares on 04/02/2026 for $20,699.91 and 3,266 shares on 01/05/2026 for $21,106.71. Additional entry shows a broker/dealer line with 2,500 shares and a Nasdaq reference.
BCYC affiliate submitted a Rule 144 notice describing planned and recent transactions in Common Stock. The filing lists proposed restricted-stock sales of 12,512 shares on 04/02/2026 and 3,593 shares on 04/03/2026. It also reports two prior sales: 10,325 shares sold on 04/02/2026 for $70,189.35 and 10,989 shares sold on 01/05/2026 for $71,013.74.
Bicycle Therapeutics plc Chief Operating Officer Jennifer Scott Perry has filed an initial ownership report showing her equity position in the company. The filing lists direct ownership of 93,872 Ordinary Shares, which includes 84,697 restricted share units that vest in scheduled quarterly installments beginning on April 2, 2026 and April 3, 2026, and in larger tranches from January 2, 2027 onward.
In addition to common shares and RSUs, Perry holds multiple employee stock options over Ordinary Shares with different exercise prices and long-dated expirations. Examples include options over 20,000 underlying Ordinary Shares at an exercise price of $26.4500 expiring on September 1, 2032, and options over 100,000 underlying Ordinary Shares at an exercise price of $7.0800 expiring on January 2, 2036. The vesting footnotes show these options generally vest one-fourth on a specified initial date, with the remaining shares vesting in equal monthly installments over 36 months.
Bicycle Therapeutics plc (BCYC) is a clinical-stage biotech advancing a proprietary Bicycle® peptide platform focused on oncology and radiopharmaceuticals. Key internal programs include nuzefatide pevedotin for EphA2-positive tumors and metastatic pancreatic cancer, zelenectide pevedotin for Nectin-4–expressing cancers, BT1702 as a lead-212 radioconjugate targeting MT1-MMP, and BT7480, a tumor-targeted CD137 immune agonist.
In March 2026, the company announced a strategic reprioritization to concentrate on next-generation Bicycle conjugates. It plans to convert the Duravelo-2 zelenectide pevedotin trial from Phase II/III to randomized Phase II, discontinue Nectin-4 trials in breast and non-small cell lung cancer, and stop internal development of BT7480 after upcoming data while seeking partners. This shift is paired with an approximate 30% workforce reduction, which together with the pipeline focus is expected to cut annual operating expenses by about 50%.
Bicycle also highlights growing radiopharmaceutical capabilities, including BIA imaging agents and BRC therapeutics, backed by long-term supply agreements for reprocessed uranium and lead-212. Collaborations with Bayer and Ionis extend the platform into radiopharmaceuticals and oligonucleotide delivery, while an extensive global patent and trademark estate supports its technology.
Bicycle Therapeutics reported strong collaboration revenue growth but continued losses alongside a major strategic shift. Collaboration revenue reached $47.96M in Q4 2025, up from $3.71M a year earlier, and $72.59M for 2025 versus $35.28M in 2024. Operating expenses rose to $319.65M, driving a full-year net loss of $218.96M, or $3.16 per share.
The company held cash and cash equivalents of $628.11M as of December 31, 2025, and expects a strategic reprioritization, including a proposed workforce reduction of about 30%, to reduce annual operating expenses by roughly 50% and extend its cash runway into 2030.
Bicycle is deprioritizing internal development of zelenectide pevedotin in metastatic urothelial cancer after completing dose selection in the Duravelo-2 trial and will convert that study to a randomized Phase 2. Resources will shift toward BT5528 and a broader pipeline of Bicycle® conjugates and radioconjugates, supported by long-term isotope supply partnerships. The company also appointed Jennifer Perry, Pharm.D., as Chief Operating Officer, with associated compensation and severance terms.